About Sirigen
Sirigen is a company based in San Diego (United States) founded in 2003 was acquired by Becton Dickinson in August 2012. Sirigen has raised $12.05 million across 3 funding rounds from investors including BD, Seraphim and YFM Equity Partners. Sirigen operates in a competitive market with competitors including NuProbe, Nanosphere, ATDBio, Marker Gene Technologies and DestiNA Genomics, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sirigen Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$12.05 M (USD)
in 3 rounds
-
Latest Funding Round
$6.11 M (USD), Series B
Oct 01, 2010
-
Investors
BD
& 5 more
-
Employee Count
Not available
-
Acquired by
Becton Dickinson
(Aug 27, 2012)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Sirigen
Sirigen has successfully raised a total of $12.05M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $6.11 million completed in October 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Sirigen
Sirigen has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include BD, Seraphim and YFM Equity Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage space-tech startups are invested in by Seraphim.
|
Locked | Locked | Locked | |
|
Early-stage venture capital is invested in UK technology sectors.
|
Locked | Locked | Locked | |
|
Private equity firm focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for Sirigen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sirigen
Investment portfolio details for Sirigen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Sirigen
Detailed financials for Sirigen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sirigen Comparisons
Peer comparison for Sirigen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sirigen
Sirigen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NuProbe, Nanosphere, ATDBio, Marker Gene Technologies and DestiNA Genomics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Sensitive multiplex platforms for QPCR are developed using toehold probes.
|
|
| Locked | Locked | Locked |
Diagnostic tests for personalized medicine targeting infections are provided.
|
|
| Locked | Locked | Locked |
Developer of oligonucleotides
|
|
| Locked | Locked | Locked |
Develops kits and reagents for research application
|
|
| Locked | Locked | Locked |
Non-enzymatic nucleic acid detection technology is developed using DGL probes.
|
Detailed competitors of Sirigen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sirigen
Complete news archive for Sirigen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sirigen
Sirigen was founded in 2003 and raised its 1st funding round 5 years after it was founded.
Sirigen is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Nick Kerton is the current CEO of Sirigen.
Sirigen is a funded company, having raised a total of $12.05M across 3 funding rounds to date.
Sirigen was founded in 2003 in San Diego, United States, within the diagnostics and life sciences sector. High-sensitivity fluorescence detection technologies are created using a platform based on novel polymer chains to improve signal detection in assays. Products are supplied for applications including immunoassays, flow cytometry, proteomics, molecular diagnostics, microarrays, and imaging systems. Operations focus on enhancing traditional assay performance across these areas.
Sirigen's top competitors include NuProbe, Nanosphere and ATDBio.
Sirigen has 6 investors. Key investors include BD, Seraphim, YFM Equity Partners, Oxford Capital, and IQ Capital.